MY146988A - Fexofenadine suspension formulation - Google Patents
Fexofenadine suspension formulationInfo
- Publication number
- MY146988A MY146988A MYPI20081743A MYPI20081743A MY146988A MY 146988 A MY146988 A MY 146988A MY PI20081743 A MYPI20081743 A MY PI20081743A MY PI20081743 A MYPI20081743 A MY PI20081743A MY 146988 A MY146988 A MY 146988A
- Authority
- MY
- Malaysia
- Prior art keywords
- fexofenadine
- suspension formulation
- fexofenadine suspension
- suspension
- antihistamines
- Prior art date
Links
- 229960003592 fexofenadine Drugs 0.000 title abstract 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title abstract 2
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960000354 fexofenadine hydrochloride Drugs 0.000 abstract 1
- 239000007971 pharmaceutical suspension Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 230000009747 swallowing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75030305P | 2005-12-14 | 2005-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY146988A true MY146988A (en) | 2012-10-15 |
Family
ID=38120312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20081743A MY146988A (en) | 2005-12-14 | 2006-12-12 | Fexofenadine suspension formulation |
Country Status (38)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101546774B1 (ko) | 2008-07-29 | 2015-08-24 | 엘지전자 주식회사 | 휴대 단말기 및 그 동작제어 방법 |
| WO2013058996A1 (en) | 2011-10-19 | 2013-04-25 | R.P. Scherer Technologies, Llc | Two phase pharmaceutical delivery system |
| JP6410814B2 (ja) | 2013-07-01 | 2018-10-24 | アベンティスユービー・エルエルシー | フェキソフェナジンを含む経口投与用液体医薬組成物 |
| CN105358138A (zh) * | 2013-07-03 | 2016-02-24 | R.P.谢勒技术有限公司 | 包含非索非那定的胶囊制剂 |
| CN103610645B (zh) * | 2013-11-25 | 2016-05-11 | 浙江万晟药业有限公司 | 一种非索非那定盐酸盐的药物组合物及制备方法 |
| CN106806346B (zh) * | 2015-12-01 | 2020-09-11 | 国药集团广东环球制药有限公司 | 一种非索非那定盐酸盐干混悬剂制剂及其制备方法 |
| CN109906079B (zh) * | 2016-06-16 | 2022-09-30 | 库蒂斯制药公司 | 用于质子泵抑制剂混悬剂的组合物和方法 |
| JP7169671B2 (ja) | 2017-06-02 | 2022-11-11 | テイカ製薬株式会社 | 難水溶性成分可溶化ミセル及びそれを含有する液剤 |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| WO2022038474A1 (en) * | 2020-08-18 | 2022-02-24 | Innate S.R.L. | Injectable composition and use of said composition |
| WO2022175829A1 (en) | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
| US20250082623A1 (en) * | 2021-12-29 | 2025-03-13 | Opella Healthcare Group Sas | Compositions containing fexofenadine |
| CN115715759B (zh) * | 2022-11-03 | 2024-01-12 | 京海盛达(北京)科技有限公司 | 一种抗组胺混悬剂及其制备方法 |
| CR20240566A (es) * | 2023-01-20 | 2025-02-25 | Opella Healthcare Group Sas | Formulaciones de fexofenadina sin parabenos |
| WO2026074306A1 (en) | 2024-10-03 | 2026-04-09 | Opella Healthcare Group Sas | Chewable fexofenadine tablets |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254129A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4829064A (en) | 1987-06-08 | 1989-05-09 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| CA2449419C (en) | 1994-05-18 | 2011-09-06 | Aventis Pharmaceuticals Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
| GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| DE60225694T2 (de) | 2001-07-31 | 2008-06-26 | Texcontor Etablissement | Neues polymorph von fexo-fenadin |
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| EP1587496B1 (en) * | 2003-01-30 | 2009-10-07 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050266031A1 (en) | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| DK2486942T3 (en) * | 2004-11-24 | 2019-01-28 | Meda Pharmaceuticals Inc | COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT |
| AU2006278874A1 (en) | 2005-07-27 | 2007-02-15 | Sandoz Ag | A process for the preparation of substituted phenyl ether compounds and rosiglitazone |
| JP5133244B2 (ja) * | 2005-08-05 | 2013-01-30 | ルピン・リミテッド | フェキソフェナジンの経口用医薬懸濁組成物 |
-
2006
- 2006-12-06 DO DO2006000274A patent/DOP2006000274A/es unknown
- 2006-12-12 PL PL06839331T patent/PL1965768T3/pl unknown
- 2006-12-12 PT PT06839331T patent/PT1965768E/pt unknown
- 2006-12-12 SI SI200630374T patent/SI1965768T1/sl unknown
- 2006-12-12 CA CA2633086A patent/CA2633086C/en active Active
- 2006-12-12 PE PE2006001593A patent/PE20071003A1/es not_active Application Discontinuation
- 2006-12-12 WO PCT/US2006/047393 patent/WO2007070517A2/en not_active Ceased
- 2006-12-12 CN CN200680044516XA patent/CN101316580B/zh active Active
- 2006-12-12 NZ NZ568943A patent/NZ568943A/en not_active IP Right Cessation
- 2006-12-12 AT AT06839331T patent/ATE431137T1/de active
- 2006-12-12 MY MYPI20081743A patent/MY146988A/en unknown
- 2006-12-12 AR ARP060105470A patent/AR058323A1/es not_active Application Discontinuation
- 2006-12-12 BR BRPI0619895-3A patent/BRPI0619895B1/pt active IP Right Grant
- 2006-12-12 KR KR1020087014471A patent/KR101452792B1/ko not_active Expired - Fee Related
- 2006-12-12 ES ES06839331T patent/ES2327168T3/es active Active
- 2006-12-12 DE DE602006006870T patent/DE602006006870D1/de active Active
- 2006-12-12 EP EP06839331A patent/EP1965768B1/en active Active
- 2006-12-12 AU AU2006326551A patent/AU2006326551B2/en active Active
- 2006-12-12 JP JP2008545740A patent/JP5308824B2/ja not_active Expired - Fee Related
- 2006-12-12 RU RU2008128418/15A patent/RU2405538C2/ru not_active IP Right Cessation
- 2006-12-12 UA UAA200809121A patent/UA89584C2/uk unknown
- 2006-12-12 RS RSP-2009/0360A patent/RS51135B/sr unknown
- 2006-12-12 DK DK06839331T patent/DK1965768T3/da active
- 2006-12-12 HR HR20090411T patent/HRP20090411T1/hr unknown
- 2006-12-14 TW TW095146788A patent/TWI377061B/zh not_active IP Right Cessation
- 2006-12-14 JO JO2006458A patent/JO2549B1/en active
- 2006-12-15 UY UY30021A patent/UY30021A1/es not_active Application Discontinuation
-
2008
- 2008-04-24 TN TNP2008000186A patent/TNSN08186A1/en unknown
- 2008-05-06 ZA ZA200803985A patent/ZA200803985B/xx unknown
- 2008-05-20 CR CR9993A patent/CR9993A/es not_active Application Discontinuation
- 2008-06-11 IL IL192067A patent/IL192067A/en not_active IP Right Cessation
- 2008-06-12 EC EC2008008532A patent/ECSP088532A/es unknown
- 2008-06-13 HN HN2008000875A patent/HN2008000875A/es unknown
- 2008-06-13 US US12/138,468 patent/US8933097B2/en active Active
- 2008-06-15 EG EG2008060996A patent/EG25866A/xx active
- 2008-06-26 NO NO20082904A patent/NO339877B1/no not_active IP Right Cessation
- 2008-07-11 MA MA31103A patent/MA30152B1/fr unknown
-
2009
- 2009-08-12 CY CY20091100862T patent/CY1109320T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| ATE543489T1 (de) | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür | |
| EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| EA201590449A1 (ru) | Перорально вводимая лекарственная композиция | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| ECSP11011559A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| ATE488225T1 (de) | Kaubare, lutschbare und verschluckbare tablette mit einer calciumhaltigen verbindung als wirkstoff | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| MXPA06000332A (es) | Nueva composicion farmaceutica solida que comprende amisulprida. | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
| TW200800977A (en) | A new salt | |
| WO2013098268A3 (en) | Tablets and dry-coated agents | |
| TW200700062A (en) | Pharmaceutical compositions | |
| WO2003070153A3 (en) | Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives | |
| ATE457721T1 (de) | An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen | |
| WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
| MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. |